Nothing Special   »   [go: up one dir, main page]

Lopez et al., 2020 - Google Patents

Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in cross-protection

Lopez et al., 2020

View HTML
Document ID
10574803476937204436
Author
Lopez E
van Heerden J
Bosch-Camós L
Accensi F
Navas M
López-Monteagudo P
Argilaguet J
Gallardo C
Pina-Pedrero S
Salas M
Salt J
Rodriguez F
Publication year
Publication venue
Viruses

External Links

Snippet

African swine fever (ASF) has become the major threat for the global swine industry. Furthermore, the epidemiological situation of African swine fever virus (ASFV) in some endemic regions of Sub-Saharan Africa is worse than ever, with multiple virus strains and …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work

Similar Documents

Publication Publication Date Title
Lopez et al. Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in cross-protection
Doroftei et al. Mini-review discussing the reliability and efficiency of COVID-19 vaccines
Gaudreault et al. Subunit vaccine approaches for African swine fever virus
Martin et al. Update on TB vaccine pipeline
Focosi et al. SARS-CoV-2 variants: a synopsis of in vitro efficacy data of convalescent plasma, currently marketed vaccines, and monoclonal antibodies
Chavda et al. Omicron variant of SARS-CoV-2: An Indian perspective of vaccination and management
Ho et al. The effects of heterologous immunization with prime-boost COVID-19 vaccination against SARS-CoV-2
Salvato et al. A single dose of modified vaccinia Ankara expressing Lassa virus-like particles protects mice from lethal intra-cerebral virus challenge
Matula et al. Antibody and T cell responses against SARS-CoV-2 elicited by the third dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines using a homologous or heterologous booster vaccination strategy
Prescott et al. Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters
Guzmán-Martínez et al. IgG antibodies generation and side effects caused by Ad5-nCoV vaccine (CanSino Biologics) and BNT162b2 vaccine (Pfizer/BioNTech) among Mexican population
Chansaenroj et al. Immunogenicity following two doses of the BBIBP-CorV vaccine and a third booster dose with a viral vector and mRNA COVID-19 vaccines against delta and omicron variants in prime immunized adults with two doses of the BBIBP-CorV vaccine
Deutschmann et al. Taking a promising vaccine candidate further: efficacy of ASFV-G-ΔMGF after intramuscular vaccination of domestic pigs and Oral vaccination of wild boar
Kudlay et al. COVID-19 vaccines: an updated overview of different platforms
Lopez et al. Deletion mutants of the attenuated recombinant ASF virus, BA71ΔCD2, show decreased vaccine efficacy
Tiyo et al. What happens to the immune system after vaccination or recovery from COVID-19?
De Angelis et al. Repeated exposure to subinfectious doses of SARS-CoV-2 may promote T cell immunity and protection against severe COVID-19
Matveeva et al. Retrospective cohort study of the effectiveness of the sputnik V and EpiVacCorona vaccines against the SARS-CoV-2 delta variant in moscow (June–July 2021)
Barroso-Arévalo et al. The Role of interleukine-10 and interferon-γ as potential markers of the evolution of African swine fever virus infection in wild boar
Giurgea et al. Navigating the quagmire: comparison and interpretation of COVID-19 vaccine phase 1/2 clinical trials
Kumar et al. Infection with non-lethal West Nile virus Eg101 strain induces immunity that protects mice against the lethal West Nile virus NY99 strain
Zhu et al. A new role for old friends: effects of helminth infections on vaccine efficacy
Oftung et al. FLU-v, a broad-spectrum influenza vaccine, induces cross-reactive cellular immune responses in humans measured by dual IFN-γ and granzyme B ELISpot assay
Shchelkunov et al. Enhancing the immunogenicity of vaccinia virus
Haegeman et al. Duration of immunity induced after vaccination of cattle with a live attenuated or inactivated lumpy skin disease virus vaccine